DFTX

Definium Therapeutics, Inc. NASDAQ Listed Nov 15, 2016

Healthcare ·Biotechnology ·US · definiumtx.com

$23.26

Mkt Cap $2.5B

52w Low $12.88 78.2% of range 52w High $26.15

50d MA $14.26 200d MA $14.26

P/E (TTM) -10.5x

EV/EBITDA -5.3x

P/B 5.8x

Debt/Equity 0.0x

ROE -55.3%

P/FCF -9.1x

RSI (14) —

ATR (14) —

Beta 2.56

50d MA $14.26

200d MA $14.26

Avg Volume 2.5M

Definium Therapeutics, Inc. is a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase I clinical trials for the treatment of core symptoms of autism spectrum disorder. Mind Medicine (MindMed) Inc. is headquartered in New York, New York.

SIC Code

2833

CIK (SEC)

1813814

Phone

212 220 6633

One World Trade Center · New York, NY 10007 · US

Date	Time	Est	Rptd	Surp	Base	Gap%	D1%	D2%	D3%	D4%	D5%	Guide ▲★
May 7, 2026	AMC	-0.49	-0.71	-44.3%	23.20	-1.5%	-5.0%	—	—	—	—	—
Feb 26, 2026	AMC	-0.48	-0.51	-5.4%	17.29	-1.6%	+0.9%	-0.6%	+2.3%	+2.7%	+1.5%	—
Nov 6, 2025	AMC	-0.52	-0.78	-50.0%	11.34	-3.4%	+3.2%	+3.6%	+10.1%	+7.1%	+2.6%	—
Jul 31, 2025	AMC	-0.38	-0.50	-31.6%	9.09	-6.4%	-7.2%	+3.0%	+6.1%	+8.8%	+9.9%	—
May 8, 2025	AMC	-0.36	-0.35	+2.8%	6.46	+0.0%	-4.8%	-0.2%	-1.4%	+1.2%	+1.4%	—
Mar 6, 2025	AMC	-0.33	-0.41	-24.2%	6.61	-0.9%	+3.3%	-4.7%	-4.1%	-2.4%	-4.5%	—
Nov 7, 2024	AMC	-0.29	-0.27	+6.9%	7.52	+2.3%	+12.9%	+19.3%	+8.9%	+11.7%	+11.6%	—
Aug 13, 2024	AMC	-0.30	-0.48	-60.0%	6.59	+4.7%	+1.1%	-2.6%	-3.5%	-3.5%	-6.4%	—
May 8, 2024	AMC	-0.66	-0.60	+9.1%	9.61	-2.9%	-5.1%	-3.6%	-12.1%	-11.7%	-5.6%	—
Feb 28, 2024	AMC	-0.48	-0.59	-22.9%	5.35	+2.6%	+6.9%	+16.4%	+16.6%	+11.0%	+11.0%	—
Nov 2, 2023	AMC	-0.65	-0.53	+18.5%	2.70	+2.2%	+14.4%	+8.1%	+4.4%	-0.4%	-5.9%	—
Aug 3, 2023	AMC	-0.54	-0.72	-33.3%	4.71	-0.8%	-7.6%	-12.1%	-7.9%	-11.3%	-8.9%	—
May 4, 2023	AMC	-0.41	-0.51	-24.4%	3.62	-2.5%	-5.8%	-6.4%	-9.1%	-11.3%	-14.6%	—

Date	Firm	Action	Grade	Target	Base	Open	Gap%	D1%	D2%	D3%	D4%	D5%
Apr 22	Leerink Partners	Maintains	Outperform → Outperform	—	$23.84	$24.08	+1.0%	-3.2%	-2.4%	-5.7%	-12.0%	-10.8%
Apr 16	Canaccord Genuity	Maintains	Buy → Buy	—	$22.15	$22.31	+0.7%	+1.4%	+2.4%	+4.7%	+7.6%	+4.2%
Mar 2	HC Wainwright & Co.	Maintains	Buy → Buy	—	$17.45	$16.76	-4.0%	-1.5%	+1.4%	+1.8%	+0.6%	+1.2%
Jan 23	RBC Capital	Maintains	Outperform → Outperform	—	$16.97	$17.31	+2.0%	+2.5%	-2.7%	+3.0%	-0.8%	+1.6%
Jan 4	HC Wainwright & Co.	Maintains	Buy → Buy	—	$22.80	$22.50	-1.3%	-2.6%	-13.8%	-17.8%	-19.1%	-21.7%

Data updated apr 25, 2026 5:03am · Source: massive.com